Exploiting the Achilles' heel of cancer: disrupting glutamine metabolism for effective cancer treatment
Open accessThe DOI matches its Crossref record; 264 of the 264 references it cites were found in a registry or an index.
Abstract
Cancer cells have adapted to rapid tumor growth and evade immune attack by reprogramming their metabolic pathways. Glutamine is an important nitrogen resource for synthesizing amino acids and nucleotides and an important carbon source in the tricarboxylic acid (TCA) cycle and lipid biosynthesis pathway. In this review, we summarize the significant role of glutamine metabolism in tumor development and highlight the vulnerabilities of targeting glutamine metabolism for effective therapy. In particular, we review the reported drugs targeting glutaminase and glutamine uptake for efficient cancer treatment. Moreover, we discuss the current clinical test about targeting glutamine metabolism and the prospective direction of drug development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“However, despite promising results in preclinical and early clinical trials, their clinical effectiveness is often compromised by resistance mechanisms due to tumor heterogeneity and metabolic plasticity, as well as toxicity to normal tissue [63].”
From The HIF Axes in Cancer - Angiogenesis, Metabolism and Immune-Modulation (2025) · cites this paper as [63]
The cited source says what the claim attributes to it.
In the citing paper
“Targeting the glutamine dependency of cancer cells is a promising therapeutic strategy for cancer and many agents targeting various steps of glutamine metabolism are currently in development [63].”
From The HIF Axes in Cancer - Angiogenesis, Metabolism and Immune-Modulation (2025) · cites this paper as [63]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–264 of 264
Suzuki, M., Toki, H., Furuya, A., & Ando, H. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.11.089 · Cited by 45
Corti, A., Dominici, S., Piaggi, S., Belcastro, E., Chiu, M., Taurino, G., Pacini, S., Bussolati, O., & Pompella, A. (2019) · Scientific Reports · doi:10.1038/s41598-018-37385-x · Cited by 45
Self‐Delivery Nanomedicine for Glutamine‐Starvation Enhanced Photodynamic Tumor Therapy
Zhao, L., Chen, S., Zheng, R., Kong, R., Rao, X., Chen, A., Cheng, H. B., Zhang, D., Li, S., & Yu, X. (2021) · Advanced Healthcare Materials · doi:10.1002/adhm.202102038 · Cited by 45
Kurozumi, S., Kaira, K., Matsumoto, H., Kurosumi, M., Yokobori, T., Kanai, Y., Sekine, C., Honda, C., Katayama, A., Furuya, M., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-06615-8 · Cited by 45
Hara, Y., Minami, Y., Yoshimoto, S., Hayashi, N., Yamasaki, A., Ueda, S., Masuko, K., & Masuko, T. (2019) · Cancer Medicine · doi:10.1002/cam4.2689 · Cited by 42
Tannir, N. M., Agarwal, N., Porta, C., Lawrence, N. J., Motzer, R. J., Lee, R. J., Jain, R., Davis, N. B., Appleman, L. J., Goodman, O. B., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.2021.39.15_suppl.4501 · Cited by 41
Cheong, H., Lindsten, T., & Thompson, C. B. (2012) · Autophagy · doi:10.4161/auto.8.1.18078 · Cited by 37
Kim, G., Jang, S., Kim, Y. J., Jin, H., Bae, S., Hong, J., Park, I., & Lee, J. H. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158761 · Cited by 37
Kong, Y., Wu, M., Wan, X., Sun, M., Zhang, Y., Wu, Z., Li, C., Liang, X., Gao, L., Ma, C., et al. (2023) · Redox Biology · doi:10.1016/j.redox.2023.102732 · Cited by 37
Identification and Characterization of IMD-0354 as a Glutamine Carrier Protein Inhibitor in Melanoma
Feng, Y., Pathria, G., Heynen‐Genel, S., Jackson, M., James, B. P., Yin, J., Scott, D. A., & Ronai, Z. A. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0354 · Cited by 36
High expression of SLC38A1 predicts poor prognosis in patients with de novo acute myeloid leukemia
Li, Y., Shao, H., Da, Z., Pan, J., & Fu, B. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.28632 · Cited by 34
Yu, C., Wang, N., Chen, X., Jiang, Y., Luan, Y., Qin, W., & He, W. (2023) · Materials Today Bio · doi:10.1016/j.mtbio.2023.100577 · Cited by 34
Timofeeva, N., Ayres, M., Baran, N., Santiago‐O’Farrill, J. M., Bildik, G., Lü, Z., Konopleva, M., & Gandhi, V. V. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1161254 · Cited by 34
Peeters, T. H., Lenting, K., Breukels, V., van Lith, S. A. M., van den Heuvel, C. N. A. M., Molenaar, R. J., van Rooij, A., Wevers, R. A., Span, P. N., Heerschap, A., et al. (2019) · Cancer & Metabolism · doi:10.1186/s40170-019-0198-7 · Cited by 32
Inhibition of Glutamine Uptake Improves the Efficacy of Cetuximab on Gastric Cancer
Ma, H., Wu, J., Zhou, M., Wu, J., Wu, Z., Li, L., Huang, N., Liao, W., & Sun, L. (2021) · Integrative Cancer Therapies · doi:10.1177/15347354211045349 · Cited by 32
Singh, K., Tanui, R., Gameiro, A., Eisenberg, G., Colas, C., Schlessinger, A., & Grewer, C. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.12.063 · Cited by 31
The peculiarities of cancer cell metabolism: A route to metastasization and a target for therapy
Carvalho, T. M. A., Cardoso, H. J., Figueira, M. I., Vaz, C. V., & Socorro, S. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.03.053 · Cited by 31
Liu, Y., Yang, Y., Jiang, L., Xu, H., & Wei, J. (2021) · Journal of Oncology · doi:10.1155/2021/5680968 · Cited by 31
Blockade of the amino acid transporter SLC6A14 suppresses tumor growth in colorectal Cancer
Lü, Y., Jiang, Z., Wang, K., Yu, S., Hao, C., Ma, Z., Fu, X., Qin, M., Xu, Z., & Fan, L. (2022) · BMC Cancer · doi:10.1186/s12885-022-09935-0 · Cited by 31
Leptin regulates sugar and amino acids transport in the human intestinal cell line C aco‐2
Fanjul, C., Barrenetxe, J., Iñigo, C., Sakar, Y., Ducroc, R. A., Barber, A., & Lostao, M. P. (2012) · Acta Physiologica · doi:10.1111/j.1748-1716.2012.02412.x · Cited by 30
Vogl, D. T., Younes, A., Stewart, K., Orford, K. W., Bennett, M. K., Siegel, D. S. D., & Berdeja, J. G. (2015) · Blood · doi:10.1182/blood.v126.23.3059.3059 · Cited by 30
Allende-Vega, N., Marco-Brualla, J., Falvo, P., Alexia, C., Constantinides, M., de Maudave, A. F., Coënon, L., Gitenay, D., Mitola, G., Massa, P. E., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-05470-x · Cited by 30
Novel Glutamine Antagonist JHU395 Suppresses MYC-Driven Medulloblastoma Growth and Induces Apoptosis
Pham, K., Maxwell, M. J., Sweeney, H., Alt, J., Rais, R., Eberhart, C. G., Slusher, B. S., & Raabe, E. H. (2021) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlab018 · Cited by 29
Shindo, H., Harada‐Shoji, N., Ebata, A., Sato, M., Soga, T., Miyashita, M., Tada, H., Kawai, M., Kosaka, S., Onuki, K., et al. (2021) · Cancers · doi:10.3390/cancers13174375 · Cited by 29
Cooper, A. J. L., Dorai, T., Pinto, J. T., & Denton, T. T. (2023) · Biology · doi:10.3390/biology12081131 · Cited by 29
Lemberg, K. M., Zhao, L., Wu, Y., Veeravalli, V., Alt, J., Aguilar, J. M. H., Dash, R. P., Lam, J., Tenora, L., Rodriguez, C., et al. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0319 · Cited by 28
Kawakami, I., Yoshino, H., Fukumoto, W., Tamai, M., Okamura, S., Osako, Y., Sakaguchi, T., Inoguchi, S., Matsushita, R., Yamada, Y., et al. (2022) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2022.04.068 · Cited by 28
Early Noninvasive Metabolic Biomarkers of Mutant IDH Inhibition in Glioma
Radoul, M., Hong, D., Gillespie, A. M., Najac, C., Viswanath, P., Pieper, R. O., Costello, J., Luchman, H. A., & Ronen, S. M. (2021) · Metabolites · doi:10.3390/metabo11020109 · Cited by 26
Tannir, N. M., Fan, A. C., Lee, R. J., Carthon, B. C., Iliopoulos, O., Mier, J. W., Patel, M. R., Meric‐Bernstam, F., DeMichele, A. M., Voss, M. H., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.6_suppl.603 · Cited by 24
Hong, J., Shen, Y., Hsu, C., Huang, P., Tomaszewski, A., Gabrielson, E. W., Shih, I., Gaillard, S. L., & Wang, T. (2022) · Genes & Diseases · doi:10.1016/j.gendis.2022.02.009 · Cited by 24
Lyu, X., Liu, Y., Wang, J., Wei, Y.-C., Han, Y., Li, X., Zhang, Q., Liu, Z., Li, Z., Jiang, J., et al. (2023) · Cancers · doi:10.3390/cancers15205082 · Cited by 23
Self-citationSchniers, B. K., Wachtel, M. S., Sharma, M., Korac, K., Rajasekaran, D., Yang, S., Sniegowski, T., Ganapathy, V., & Bhutia, Y. D. (2022) · Biochemical Journal · doi:10.1042/bcj20210855 · Cited by 22
Eads, J. R., Krishnamurthi, S., Saltzman, J. N., Bajor, D. L., Vinayak, S., Barnholtz‐Sloan, J. S., Meropol, N. J., Markowitz, S. D., & Wang, Z. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.2562 · Cited by 21
Yuan, L., Guo, H., Pan, G., Wang, C., 李大鹏, 刘乃富, Wei, L., Liu, N., & Sheng, X. (2022) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520622666220513163341 · Cited by 21
Bonomi, P., Finkelstein, D., & Chang, A. Y. C. (1994) · American Journal of Clinical Oncology · doi:10.1097/00000421-199406000-00006 · Cited by 20
Johnson, M. L., Doroshow, D. B., Seiwert, T. Y., Gibson, M. K., Velcheti, V., Lisberg, A. E., Patel, S. A., Scheffler, M., Lafleur, F., Dugan, M. H., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.2021.39.15_suppl.tps3149 · Cited by 20
Distinct Roles of Glutamine Metabolism in Benign and Malignant Cartilage Tumors With IDH Mutations
Zhang, H., Puviindran, V., Nadesan, P., Ding, X., Shen, L., Tang, Y. J., Tsushima, H., Yahara, Y., Ban, G. I., Zhang, G., et al. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4532 · Cited by 20
Yu, W., Huang, J., Dong, Q.-C., Li, W., Jiang, L., Zhang, Q., Sun, L., Yuan, S., & He, X. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.871392 · Cited by 19
Moon, D., Hauck, J. S., Jiang, X., Quang, H., Xu, L., Zhang, F., Gao, X., Wild, R., Everitt, J. I., Macias, E., et al. (2023) · The Prostate · doi:10.1002/pros.24654 · Cited by 18
Kaur, H., Kumar, B., Chakrabarti, A., Medhi, B., Modi, M., Radotra, B. D., Aggarwal, R., & Sinha, V. R. (2018) · Current Drug Delivery · doi:10.2174/1567201815666180926121104 · Cited by 18
Zheng, M., Xu, H., Huang, Y., Sun, J., Zhang, H., Lv, Z., Liu, Z., Tang, Z., & Chen, X. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.11.054 · Cited by 17
Vidal, G. A., Kalinsky, K. M., Stringer-Reasor, E. M., Lynce, F. C., Cole, J., Valdes-Albini, F., Soliman, H. H., Nikolinakos, P. G., Silber, A. L. M., DeMichele, A. M., et al. (2019) · Cancer Research · doi:10.1158/1538-7445.sabcs18-p6-20-07 · Cited by 16
Editorial: Nanomedicine-Based Drug Delivery Systems: Recent Developments and Future Prospects
Shakeel, F. (2023) · Molecules · doi:10.3390/molecules28104138 · Cited by 14
Phase II Trial of Acivicin in Patients with Advanced Colorectal Carcinoma
Adolphson, C. C., Ajani, J. A., Stroehlein, J. R., Barlogie, B., Bodey, G. P., Korinek, J. K., & Bedikian, A. Y. (1986) · American Journal of Clinical Oncology · doi:10.1097/00000421-198606000-00003 · Cited by 13
Feng, Y., Li, C., Wang, W., Xu, L., Zhang, M., Yao, Y., Wu, X., Zhang, Q., Huang, W., Wang, X., et al. (2022) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520622666220905142338 · Cited by 13
Wei, D., Chen, D., Mou, H., Chakraborty, S., Wei, B., Tan, L., Lorenzi, P. L., Qian, X., & Yang, P. (2023) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-22-0490 · Cited by 13
Scalise, M., Pappacoda, G., Mazza, T., Console, L., Pochini, L., & Indiveri, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031127 · Cited by 12
Evaluation of genetic toxicity of 6-diazo-5-oxo- l -norleucine (DON)
Kulkarni, R. M., Dakoulas, E. W., Miller, K. E., & Terse, P. (2017) · Toxicology Mechanisms and Methods · doi:10.1080/15376516.2017.1333552 · Cited by 10
Freidman, N., Briot, C., & Ryan, R. M. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.102178 · Cited by 10
Pore, N., Schifferli, K. P., Monks, N. R., Tammali, R., Borrok, M. J., Hurt, E. M., Flynn, M., Rebelatto, M. C., Townsley, D. M., Hinrichs, M. J., et al. (2018) · Blood · doi:10.1182/blood-2018-99-119836 · Cited by 9
Gao, R.-D., Hin, N., Prchalová, E., Pal, A., Lam, J., Rais, R., Slusher, B. S., & Tsukamoto, T. (2021) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2021.128321 · Cited by 8
Zhu, L., Wang, Z., Han, W., & Xu, A. (2023) · BMC Gastroenterology · doi:10.1186/s12876-023-02689-4 · Cited by 8
Anti-Myeloma Activity of a Novel Glutaminase Inhibitor CB-839
Das, D. S., Ravillah, D., Ray, A., Song, Y. Y., Munshi, N. C., Richardson, P. G. G., Chauhan, D., & Anderson, K. C. (2014) · Blood · doi:10.1182/blood.v124.21.3439.3439 · Cited by 7
Schifferli, K. P., Monks, N. R., Tammali, R., Borrok, M. J., Flynn, M., Hurt, E. M., Coats, S. R., Herbst, R., Tice, D. A., & Pore, N. (2018) · Cancer Research · doi:10.1158/1538-7445.am2018-lb-298 · Cited by 7
Ciombor, K. K., Whisenant, J. G., Cardin, D. B., Goff, L. W., Das, S., Schulte, M. I., Cohen, A. S., Coffey, R. J., Ayers, G. D., Krumsick, R., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.4_suppl.574 · Cited by 6
Duan, Z., Zhou, Z., Lu, F., Zhang, Y., Guo, X., Gui, C., & Zhang, H. (2022) · Investigational New Drugs · doi:10.1007/s10637-022-01284-w · Cited by 6
Kizilbash, S. H., Piccioni, D. E., Sahebjam, S., Villano, J. L., Jaeckle, K. A., Welch, M. R., Kong, X., Holdhoff, M., Lammers, A., Remick, A., et al. (2022) · Neuro-Oncology · doi:10.1093/neuonc/noac209.288 · Cited by 5
Saxena, K., Konopleva, M. Y., Bhagat, T. D., Guerra, V. A., Maduike, R., Tiziani, S., Borthakur, G. M., Jabbour, E. J., Pemmaraju, N., Kadia, T. M., et al. (2020) · Blood · doi:10.1182/blood-2020-137266 · Cited by 4
Colas, C., Grewer, C., Gameiro, A. M., Albers, T., Singh, K., Otte, N. J., Shere, H., Bonomi, M., Holst, J., & Schlessinger, A. (2015) · Biophysical Journal · doi:10.1016/j.bpj.2014.11.329 · Cited by 4
Gonsalves, W. I., Neparidze, N., Allred, J. B., Kumar, S. K., Reid, J. M., Shapiro, G. I., Costello, B. A., Piekarz, R., Baz, R., & Devarakonda, S. S. (2022) · Blood · doi:10.1182/blood-2022-164966 · Cited by 4
Wang, H., & Wang, J. (2022) · Tropical Journal of Pharmaceutical Research · doi:10.4314/tjpr.v21i6.6 · Cited by 3
Structural basis for stereospecific inhibition of ASCT2 from rational designPreprint
Garibsingh, R. A., Ndaru, E., Garaeva, A. A., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.05.29.124305 · Cited by 1
Okabe, S., Tanaka, Y., & Gotoh, A. (2022) · HemaSphere · doi:10.1097/01.hs9.0000845856.56702.e6 · Cited by 1
P-187 Targeting glutamine metabolism and EGFR in RAS wildtype colorectal cancer
Ciombor, K. K., Whisenant, J. G., Ayers, G. D., Eng, C., Goff, L. W., Cardin, D. B., Hickman, T., Smith, G. T., Peterson, T. E., Bae, S., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.04.243 · Cited by 1
Research works printed but not linked: 1
- Mickle, 2022, VGLL4 and glutamine deprivation suppress YAP1/TEAD signaling to attenuate the SCC cancer phenotype
Cited by
The HIF Axes in Cancer - Angiogenesis, Metabolism and Immune-Modulation
Acuña-Pilarte, K., & Koh, M. Y. (2025) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2025.06.005 · Cited by 64
Role of monocarboxylate transporters in cancer immunology and their therapeutic potential
Faghihkhorasani, F., Moosavi, M., Abdulwahid, A. R. R., Kavei, M., Karimi, S., Karimi, M. S., Vezvaei, P., Varkiani, M. M., Aref, A. R., & Ebrahimi, N. (2025) · British Journal of Pharmacology · doi:10.1111/bph.70110 · Cited by 27
Li, Y., Lu, Y., Lü, W., Zhong, N., Li, N., Xu, Z., Zhang, J., Sun, H., Wu, F., Teng, Z., et al. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113739 · Cited by 21
Lin, Z., Chang, C., Zhao, S., Fang, L., & Wang, P. (2025) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2025.0115 · Cited by 27
Deciphering the landscape of allosteric glutaminase 1 inhibitors as anticancer agents
Vagaggini, C., D’Ursi, P., Poggialini, F., Fossa, P., Francesconi, V., Trombetti, G., Orro, A., Dreassi, E., Schenone, S., Tonelli, M., et al. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.108523 · Cited by 17
Metadata
- Authors
- Fan, Y., Xue, H., Li, Z., Huo, M., Gao, H., & Guan, X.
- Affiliations
- Beihua University (CN)
- Taizhou University (CN)
- Corresponding author
- Gao, Hongxia
- Guan, Xingang
- Venue
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Published
- 2024-03-06
- Volume
- 15
- Pages
- 1345522-1345522
- ISSN
- 1663-9812 (ISSN-L)
- PMC
- PMC10952006
- OpenAlex
- W4392517467
- Cited by
- 40
- References
- 263
- Citations by year
- 2026: 15 · 2025: 22 · 2024: 3
- FWCI
- 1.95
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Pharmacology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Natural Science Foundation of China
- Beihua University
- Science and Technology Plan Project of Taizhou (22gya03)
- Natural Science Foundation of Zhejiang Province (LY23C100001)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Amino Acid Enzymes and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Keywords
- glutamine metabolism, cancer metabolism, glutaminase inhibitors, tumor metabolic reprogramming, TCA cycle, lipogenesis, cancer therapy, drug development
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.